Shionogi & Co. (SGIOY) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 01/27/25
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe DiseaseBusiness Wire • 05/10/24